Full Length Research Paper
References
|
Alidina A, Siddiqui T, Burney I, Jafri W, Hussain F, Ahmed M (2004). Esophageal cancer - a review. Journal of Pakistan Medical Association 54(3):136-141. |
|
|
Brooks Brunn JA (2000). Esophageal cancer: An overview. Medsurg Nursing 9(5):248-254. |
|
|
Feng W, Qi Z, Qiu R, Li ZS, Dong SL, Li YK, Hu YP, He M, Wang YX (2020). Risk factors for tumor recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma after esophagectomy. Journal of International Medical Research 48(12):300060520977403. |
|
|
Gu ZD, Chen KN, Li M, Gu J, Li JY (2005). Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World Journal of Gastroenterology 11(6):871-874. |
|
|
Guo XF, Mao T, Gu ZT, Ji CY, Fang WT, Chen WH (2014). Clinical study on postoperative recurrence in patients with pN0 esophageal squamous cell carcinoma. Journal of Cardiothoracic Surgery 9(1):1-7. |
|
|
Li CL, Zhang FL, Wang YD, Han C, Sun GG, Liu Q, Cheng YJ, Jing SW, Yang CR (2013). Characteristics of recurrence after radical esophagectomy with two-field lymph node dissection for thoracic esophageal cancer. Oncology Letters 5(1):355-359. |
|
|
Li J, Xie Y, Wang X, Jiang C, Yuan X, Zhang A, Liu C, Pang L, Li F, Hu J (2019). Overexpression of VEGF-C and MMP-9 predicts poor prognosis in Kazakh patients with esophageal squamous cell carcinoma. PeerJ 7:e8182. |
|
|
Li Yi, Guo H, Dong D, Wu H, Li E (2013). Expression and prognostic relevance of cyclophilin A and matrix metalloproteinase 9 in esophageal squamous cell carcinoma. Diagnostic Pathology 8(1):1-6. |
|
|
Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D; ESMO Guidelines Committee (2016). Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 27(suppl 5):v50-v57. |
|
|
Lu J, Tao H, Song D, Chen C (2013). Recurrence risk model for esophageal cancer after radical surgery. Chinese Journal of Cancer Research 25(5):549-555. |
|
|
?ukaszewicz-Zajac M, Mroczko B, Koz?owski M, Nikli?ski J, Lauda?ski J, Szmitkowski M (2009). Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma. Polish Archives of Internal Medicine 119(9):558-563. |
|
|
Ma R, Xu H, Wu J, Sharma A, Bai S, Dun B, Jing C, Cao H, Wang Z, She JX, Feng J (2017). Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer. Oncotarget 8(12):18901-18913. |
|
|
Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Mori M, Doki Y (2011). Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Annals of Surgical Oncology 18(12):3353-3361. |
|
|
Mroczko B, Koz?owski M, Groblewska M, ?ukaszewicz M, Nikli?ski J, Jelski W, Lauda?ski J, Chyczewski L, Szmitkowski M (2008). The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clinica Chimica Acta 389(1-2):61-66. |
|
|
Ozawa Y, Kamei T, Nakano T, Taniyama Y, Miyagi S, Ohuchi N (2016). Characteristics of Postoperative Recurrence in Lymph NodeNegative Superficial Esophageal Carcinoma. World Journal of Surgery 40(7):1663-1671. |
|
|
Peisker A, Raschke GF, Fahmy MD, Guentsch A, Roshanghias K, Hennings J, Schultze-Mosgau S (2017). Salivary MMP-9 in the detection of oral squamous cell carcinoma. Medicina Oral, Patologia Oral y Cirugia Bucal 22(3):e270-275. |
|
|
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology 16(9):1090-1098. |
|
|
Shen WB, Gao HM, Zhu SC, Li YM, Li SG, Xu JR (2017). Analysis of postoperative failure in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma and consideration of postoperative radiotherapy. Chinese Journal of Radiation Oncology 26(4):394-399 |
|
|
Siegel RL, Miller KD, Jemal A (2017). Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67(1):7-30. |
|
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65(2):87-108. |
|
|
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine 366(22):2074-2084. |
|
|
Xue LY, Qin XM, Liu Y, Liang J, Lin H, Xue XM, Zou SM, Zhang MY, Zhang BH (2018). Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma. World Journal of Gastroenterology 24(45):5154-5166. |
|
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y (2018). Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. Journal of Clinical Oncology 36(27):2796-2803. |
|
|
Ye Z, Zhao H, Zhou W, Ye T, Geng C, Li X, Yuan L, Du M, Xu H (2020). Lower Serum Matrix Metalloproteinase?9 in Metastatic Patients with Esophageal Squamous Cell Carcinoma After Concurrent Radiotherapy Was Significant for Prognosis. OncoTargets and Therapy 13:12857-12866. |
|
|
Zeng R, Duan L, Kong Y, Liang Y, Wu X, Wei X, Yang K (2013). Clinicopathological and prognostic role of MMP-9 in esophageal squamous cell carcinoma: a meta-analysis. Chinese Journal of Cancer Research 25(6):637-645. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
